Abstract 210P
Background
Vascularization is known to be linked to tumour growth. We explored the potential of automated lung tumour vascularity assessment as risk factor for landmark survival.
Methods
131 CT scans from the NSCLC Radiogenomics dataset were evaluated. All patients underwent surgery, with or without other therapies. Primary lung tumour (PLT) is segmented by a radiologist. Vessels segmentation (arteries and veins) is performed by an in-house deep learning segmentation model. Vascularity features extracted for the PLT include: amount of blood vessel connections, % of the tumour surface connected to vessels (%area), and basic statistics on the surface area of the connections. A generalized linear model (GLM) to predict landmark survival was trained with these features, tumour volume, and clinical factors. Stepwise feature reduction was performed to arrive to the final model. We present the odds ratio (OR) as well as a combined risk score for the remaining independent predictors.
Results
Landmark survival was reached for 86/131 (66%) patients. GLM analysis showed 4 independent risk factors related to landmark survival: %area (OR= 1.69 for >2.5%), age (OR=1.57 for >70 years), gender (OR=2.10 for male) and radiation therapy (OR=1.51 for yes). Smoking status and tumor volume were not retained in the final model. We also showed that risk of dying before landmark survival increased with increased number risk factors (0%, 18%, 40%, 48% and 100% for 0, 1, 2, 3, 4 risk factors, respectively).
Conclusions
Lung tumour vascularity is an independent risk factor for landmark survival. We showed an approach were it can be used as additional prognostic factor to inform clinical decision making and therapy planning.
Clinical trial identification
Editorial acknowledgement
Fabio Bottari, PhD, of Radiomics for providing medical writing support in accordance with Good Publication Practice ( GPP 2022) guidelines.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi: Financial Interests, Personal, Full or part-time Employment: Radiomics. W. Vos: Financial Interests, Personal, Leadership Role: Radiomics. M. Occhipinti: Financial Interests, Personal, Financially compensated role: Radiomics. All other authors have declared no conflicts of interest.
Resources from the same session
144P - Artificial intelligence supported treatment decisions for precision oncology
Presenter: Damian Rieke
Session: Poster session 01
145P - Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence
Presenter: Francesca Angileri
Session: Poster session 01
147P - Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies
Presenter: Pierre Saintigny
Session: Poster session 01
149P - Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study
Presenter: Nadia Gomez Serra
Session: Poster session 01
150P - Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial
Presenter: Antonio Llombart Cussac
Session: Poster session 01
152P - Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study
Presenter: Sofie Joris
Session: Poster session 01
153P - Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis
Presenter: Pablo Torres-Mozas
Session: Poster session 01
154P - Highly sensitive serum volatolomic biomarkers for pancreatic cancer diagnosis and prognosis
Presenter: Alfredo Martínez
Session: Poster session 01